Key Points
- FUSMobile, a company developing a focused ultrasound platform for neural tissue ablation has published the results from its first clinical pilot study for the treatment of low back pain.
- The study enrolled 10 participants, who reported no significant device- or procedure-related adverse events.
- The Foundation funded a portion of this trial.
Fluoroscopy-Guided High-Intensity Focused Ultrasound Neurotomy of the Lumbar Zygapophyseal Joints: A Clinical Pilot Study
FUSMobile, a new high-intensity focused ultrasound (HIFU) company that is developing a device for
neural tissue ablation, has published the results from its first clinical pilot study treating facetogenic low back pain. The device, the Neurolyser XR, is guided by x-ray fluoroscopy imaging. In this study, which was designed to establish safety and test feasibility, 10 participants received HIFU ablation of one or more lumbar vertebrae zygapophyseal joints to relieve their low back pain. The group reported no significant device- or procedure-related adverse events. A larger study to determine the HIFU system’s effectiveness is now underway.
“The FUSMobile team feels fortunate for the overwhelming support in our quest to relieve patient pain,” says Arik Hananel, MD, FUSMobile’s CEO and co-founder.